Cinacalcet hydrochloride

Phase 2Small molecule

Cinacalcet hydrochloride is one of 54 small molecule programs targeting Secondary Hyperparathyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Secondary HyperparathyroidismActive, not recruiting

Prostate CancerActive, not recruiting

Secondary HyperparathyroidismPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Cinacalcet hydrochloride

Amgen

Phase 2

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Secondary Hyperparathyroidism2 trials

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Terminated· Amgen logo

Amgen·Phase 2·NCT01439867·18 enrolled

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 3·NCT03822507·404 enrolled

Prostate Cancer1 trial

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT01054079·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cinacalcet hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cinacalcet hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cinacalcet hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Amgen

Cinacalcet hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Secondary Hyperparathyroidism2 trials

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News